Where does Tianjin Institute of Pharmaceutical Research Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Tianjin Institute of Pharmaceutical Research Co., Ltd. ranks #27,651 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

What is Tianjin Institute of Pharmaceutical Research Co., Ltd.'s Innovation Score?

Tianjin Institute of Pharmaceutical Research Co., Ltd. has an Innovation Score of 30.2 out of 100 (33rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Tianjin Institute of Pharmaceutical Research Co., Ltd.'s patent grant rate increasing or decreasing?

Tianjin Institute of Pharmaceutical Research Co., Ltd.'s recent grant velocity is -20% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Tianjin Institute of Pharmaceutical Research Co., Ltd.'s patents?

Tianjin Institute of Pharmaceutical Research Co., Ltd.'s patents average 18.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Tianjin Institute of Pharmaceutical Research Co., Ltd.

Q: How many patents does Tianjin Institute of Pharmaceutical Research Co., Ltd. hold?

Tianjin Institute of Pharmaceutical Research Co., Ltd. holds 10 US utility patents granted between 2015 and 2025, spanning 7 technology areas.

Q: What technology areas does Tianjin Institute of Pharmaceutical Research Co., Ltd. focus on?

Tianjin Institute of Pharmaceutical Research Co., Ltd.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 10 patents. Grants appear in 7 CPC subclasses total.

Q: How is the Tianjin Institute of Pharmaceutical Research Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 10 granted patents across 7 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Tianjin ranks #27,651 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 7 technology areas.

#27,651
of 49,997 US assignees by volume: 33rd percentile
by Innovation Score (30.2/100): 18.1
avg claims per patent: -20%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R27651 · Foreign Corporation #27,651 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #27,651/49,997
PHOTO-FINISH Thomas Swan &
CPC-NARROW A61P · 7 areas
INNOV-THIN 30.2/100
CLAIMS-RICH 18.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -20% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Thomas Swan & Co. Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Kumho Tire · near

30
Tianjin Institute… · this assignee

30
Dietze & Schell… · near

30
Hensley Industries · near

30
LEX Products · near

30
3D Lighting… · lowest

7

What this shows Tianjin's Innovation Score is 30.2/100 (33rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Tianjin's grants concentrate

Tianjin Institute of Pharmaceutical Research Co., Ltd. is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2016. By volume, Tianjin sits between Thomas Swan & Co. Ltd. and Titcomb Brothers Manufacturing, Inc..

Tianjin's three-year grant acceleration

Tianjin Institute of Pharmaceutical Research Co., Ltd. shows 1 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Thomas Swan &

10
Thule Canada

10
Thyssenkrupp Elev…

10
Tianjin Hualai Te…

10
Tinder

10
Tinnus Enterprises

10
Titan Kogyo

10
Titcomb Brothers…

10
Tianjin Institute… ◀

10

What this shows Tianjin holds 10 patents at rank #27,667, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Tianjin

By rank, the assignees closest to #27,667 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Tianjin's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Tianjin, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (30 here).

Dietze & Schell Maschinenfabrik GmbH & Co. KG 30 LEX Products Corp 30 Kumho Tire Co., Inc. 30 Hensley Industries, Inc. 30

Tianjin's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 33rd percentile higher than 33% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Tianjin Institute of Pharmaceutical Research Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	30.0%
2016	1	10.0%
2019	1	10.0%
2020	1	10.0%
2021	2	20.0%
2022	1	10.0%
2025partial year	1	10.0%

Which technologies does Tianjin Institute of Pharmaceutical Research Co., Ltd. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 10

C07D - Heterocyclic Compounds 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 7

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C07C - Acyclic OR Carbocyclic Compounds 1

C07K - Peptides 1

Top 7 of 7 technology areas

Where it ranks

Overall rank by patents

#27,651

of 49,997 tracked assignees

Innovation Score

30.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Tianjin Institute of Pharmaceutical Research Co., Ltd.'s patent record in context - here's where to go next.

Tianjin Institute of Pharmaceutical Research Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #27,651 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Tianjin Institute of Pharmaceutical Research Co., Ltd. against Thomas Swan & Co. Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.